Pneumococcal Serotypes Associated with Community-Acquired Pneumonia Hospitalizations in Adults in Spain, 2016-2020 : The CAPA Study
Newer higher valency pneumococcal conjugate vaccines (PCVs) have the potential to reduce the adult community-acquired pneumonia (CAP) burden. We describe the evolution and distribution of adult community-acquired pneumonia (CAP) serotypes in Spain, focusing on serotypes contained in the 20-valent PCV (PCV20). This was a prospective, observational study of chest X-ray (CXR)-confirmed CAP in immunocompetent adults hospitalized in one of four Spanish hospitals between November 2016 and November 2020. Pneumococci were isolated from cultures and detected in urine using BinaxNow® and Pfizer serotype-specific urinary antigen tests UAD1 and UAD2. We included 1948 adults hospitalized with CXR-CAP. The median age was 69.0 years (IQR: 24 years). At least one comorbidity was present in 84.8% (n = 1653) of patients. At admission, 76.1% of patients had complicated pneumonia. Pneumococcus was identified in 34.9% (n = 680) of study participants. The PCV20 vaccine-type CAP occurred in 23.9% (n = 465) of all patients, 68.4% (n = 465) of patients with pneumococcal CAP, and 82.2% (83/101) of patients who had pneumococcus identified by culture. Serotypes 8 (n = 153; 7.9% of all CAP) and 3 (n = 152; 7.8% of all CAP) were the most frequently identified. Pneumococcus is a common cause of hospitalized CAP among Spanish adults and serotypes contained in PCV20 caused the majority of pneumococcal CAP.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Microorganisms - 11(2023), 11 vom: 16. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Menéndez, Rosario [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Community-acquired pneumonia |
|---|
| Anmerkungen: |
Date Revised 27.11.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/microorganisms11112781 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364960108 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364960108 | ||
| 003 | DE-627 | ||
| 005 | 20231226100650.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/microorganisms11112781 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1216.xml |
| 035 | |a (DE-627)NLM364960108 | ||
| 035 | |a (NLM)38004792 | ||
| 035 | |a (PII)2781 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Menéndez, Rosario |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pneumococcal Serotypes Associated with Community-Acquired Pneumonia Hospitalizations in Adults in Spain, 2016-2020 |b The CAPA Study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 27.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Newer higher valency pneumococcal conjugate vaccines (PCVs) have the potential to reduce the adult community-acquired pneumonia (CAP) burden. We describe the evolution and distribution of adult community-acquired pneumonia (CAP) serotypes in Spain, focusing on serotypes contained in the 20-valent PCV (PCV20). This was a prospective, observational study of chest X-ray (CXR)-confirmed CAP in immunocompetent adults hospitalized in one of four Spanish hospitals between November 2016 and November 2020. Pneumococci were isolated from cultures and detected in urine using BinaxNow® and Pfizer serotype-specific urinary antigen tests UAD1 and UAD2. We included 1948 adults hospitalized with CXR-CAP. The median age was 69.0 years (IQR: 24 years). At least one comorbidity was present in 84.8% (n = 1653) of patients. At admission, 76.1% of patients had complicated pneumonia. Pneumococcus was identified in 34.9% (n = 680) of study participants. The PCV20 vaccine-type CAP occurred in 23.9% (n = 465) of all patients, 68.4% (n = 465) of patients with pneumococcal CAP, and 82.2% (83/101) of patients who had pneumococcus identified by culture. Serotypes 8 (n = 153; 7.9% of all CAP) and 3 (n = 152; 7.8% of all CAP) were the most frequently identified. Pneumococcus is a common cause of hospitalized CAP among Spanish adults and serotypes contained in PCV20 caused the majority of pneumococcal CAP | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a PCV20 serotypes | |
| 650 | 4 | |a community-acquired pneumonia | |
| 650 | 4 | |a pneumococcal conjugate vaccines | |
| 650 | 4 | |a pneumococcal pneumonia | |
| 700 | 1 | |a Torres, Antoni |e verfasserin |4 aut | |
| 700 | 1 | |a España, Pedro Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Villar, Jose Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Marimón, José María |e verfasserin |4 aut | |
| 700 | 1 | |a Méndez, Raúl |e verfasserin |4 aut | |
| 700 | 1 | |a Cilloniz, Catia |e verfasserin |4 aut | |
| 700 | 1 | |a Egurrola, Mikel |e verfasserin |4 aut | |
| 700 | 1 | |a Botana-Rial, Maribel |e verfasserin |4 aut | |
| 700 | 1 | |a Ercibengoa, María |e verfasserin |4 aut | |
| 700 | 1 | |a Méndez, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Cifuentes, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Gessner, Bradford D |e verfasserin |4 aut | |
| 700 | 0 | |a CAPA Study Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Microorganisms |d 2013 |g 11(2023), 11 vom: 16. Nov. |w (DE-627)NLM247050237 |x 2076-2607 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2023 |g number:11 |g day:16 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/microorganisms11112781 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2023 |e 11 |b 16 |c 11 | ||